1. Home
  2. VERU vs AIRE Comparison

VERU vs AIRE Comparison

Compare VERU & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.25

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$2.24

Market Cap

39.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
AIRE
Founded
1971
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
39.9M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
VERU
AIRE
Price
$2.25
$2.24
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$22.50
$1.30
AVG Volume (30 Days)
46.1K
1.3M
Earning Date
05-12-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.34
EPS
N/A
N/A
Revenue
$16,296,958.00
$4,518,498.00
Revenue This Year
N/A
$129.06
Revenue Next Year
N/A
$83.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
376.42
52 Week Low
$0.36
$0.14
52 Week High
$4.59
$3.98

Technical Indicators

Market Signals
Indicator
VERU
AIRE
Relative Strength Index (RSI) 44.28 63.64
Support Level $2.13 $0.35
Resistance Level $2.70 $3.98
Average True Range (ATR) 0.09 0.30
MACD -0.00 0.04
Stochastic Oscillator 21.74 54.34

Price Performance

Historical Comparison
VERU
AIRE

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

Share on Social Networks: